Janet Mercel spent decades fainting without explanation. As a child in Upstate New York, she'd collapse at home, at school, at the grocery store. Doctors shrugged. Her parents weren't alarmed because she seemed otherwise healthy. One physician suggested iron supplements for anemia. Others blamed panic attacks. When epilepsy medication made her worse, Mercel was left with nothing but questions and a body that wouldn't cooperate.
Now, a new clinical trial run by the Veterans Affairs is offering patients like her something rare: a systematic investigation into what might actually help. The study examines whether GLP-1 receptor agonists—a class of drugs already used for diabetes and weight management—could treat alcohol use disorder. For Mercel, it represents a chance at clarity after years of institutional failure.
The Cost of Diagnostic Failure
Mercel's experience reflects a broader problem in American medicine: patients with complex or uncommon conditions often fall through the cracks. When symptoms don't fit standard categories, doctors default to dismissal or misdiagnosis. A child who faints repeatedly gets labeled anxious. A woman's real condition goes unnamed for years. The burden falls entirely on the patient to keep searching, to keep hoping someone will finally listen.
The medical system isn't designed to handle uncertainty well. It rewards quick diagnosis and treatment protocols that fit established boxes. When a patient doesn't fit, they're often sent home with a shrug and a prescription that makes things worse. Mercel experienced this directly: the epilepsy medication didn't help because epilepsy wasn't her problem. No one had bothered to find out what was.
A New Research Direction
The VA's clinical trial represents a different approach. Rather than assuming patients know what's wrong with them, or that their symptoms must fit existing categories, the study treats investigation itself as the intervention. GLP-1 receptor agonists have shown unexpected therapeutic effects beyond their original purpose. That's how medicine advances—through systematic research that takes patients seriously enough to study them.
Mercel's participation in this trial gave her something she hadn't had before: the possibility of answers. Not a guess. Not a medication that made her sicker. Not a diagnosis that didn't fit. An actual investigation into her condition, led by researchers willing to look beyond the obvious.
Why This Matters:
Thousands of patients navigate diagnostic odysseys like Mercel's every year, often without the institutional support of a clinical trial. The gap between what medicine can discover and what it actually investigates for individual patients reflects broader inequalities in healthcare access. When research funding and clinical attention flow toward common, profitable conditions, rare and complex cases get abandoned. Mercel's story isn't exceptional—it's representative of a system that works well for some and leaves others to suffer in silence. The VA trial demonstrates that systematic investigation, proper funding, and genuine curiosity about patients' experiences can unlock answers that years of dismissal never will. It's a reminder that clinical research isn't just about drug development; it's about institutional responsibility to people whose suffering doesn't fit neat categories.